Catabasis Pharms

CATB NASDAQ
6.68
-0.03
-0.45%
Closed 16:00 08/23 EDT
Open
6.60
Prev Close
6.71
High
6.80
Low
6.52
Volume
14.91K
Avg Vol (3M)
63.42K
52 Week High
9.76
52 Week Low
3.600
% Turnover
0.13%
Market Cap
77.60M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Catabasis Pharms CATB stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.
MORE >

Recently

Name
Price
%Change